Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended December 31, 2003 (Fiscal Year 2004)
Business Overview: McKesson operates through three primary segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Information Solutions. The company is a major distributor of pharmaceuticals and medical-surgical products and provides information technology solutions to healthcare providers.
Key Financial Metrics
| Metric (in millions) | Q3 2003 | Q3 2002 | 9 Months 2003 | 9 Months 2002 |
|---|---|---|---|---|
| Revenues | $18,231.9 | $14,921.0 | $51,566.2 | $42,234.5 |
| Gross Profit | $733.8 | $727.6 | $2,332.0 | $2,217.7 |
| Operating Income | $162.0 | $209.8 | $639.1 | $634.2 |
| Net Income | $120.2 | $134.3 | $432.3 | $376.4 |
| Diluted EPS | $0.41 | $0.46 | $1.46 | $1.27 |
| Cash & Equivalents | $200.5 | $316.1 | $200.5 | $316.1 |
| Total Debt (Short + Long Term) | $1,703.7 | $1,500.9 | $1,703.7 | $1,500.9 |
| Working Capital | $3,707.3 | $3,278.4 | $3,707.3 | $3,278.4 |
Note: Debt figures calculated as Short-term borrowings + Current portion of long-term debt + Long-Term Debt.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 22% year-over-year for both the quarter and nine-month periods, driven primarily by the Pharmaceutical Solutions segment (up 24%). This growth was fueled by market expansion, increased sales to institutional customers, and a 45% increase in sales to customers' warehouses.
- Margin Compression: Despite revenue growth, the consolidated gross profit margin decreased by 86 basis points for the quarter and 73 basis points for the nine months. The Pharmaceutical Solutions segment margin declined significantly (from 3.50% to 2.73% in the quarter) due to evolving industry business models, reduced vendor incentives, and shifts in pricing timing.
- Profitability: Net income for the quarter decreased 10% to $120.2 million, while the nine-month net income increased 15% to $432.3 million. The quarterly decline was impacted by specific contract losses and bad debt provisions.
- Cash Flow: Operating cash flow turned negative for the nine months ended Dec 31, 2003 ($275.8 million used), compared to a positive $365.3 million in the prior year. This shift was due to increased working capital requirements (receivables and inventory) to support revenue growth and a reduction in the utilization of the receivables sale facility.
Guidance, Outlook, Risks, and Unusual Items
Unusual Items and One-Time Charges
- Contract Losses: Recorded a $51.0 million provision for expected losses on international contracts in the Information Solutions segment in Q3 2003, plus an incremental $20.0 million provision in Q3 2004.
- Bad Debt Provisions: Recorded a $30.0 million bad debt provision in the Pharmaceutical Solutions segment due to a customer bankruptcy. Additionally, a $9.0 million provision was recorded for the pharmacy outsourcing business.
- Tax Benefits: Recognized a $7.9 million income tax benefit in the quarter and a $15.3 million benefit for the nine months resulting from favorable tax settlements with the IRS and other authorities.
- Antitrust Settlement: Received a $21.7 million cash settlement from an antitrust class action lawsuit involving cardiac drug manufacturers, recorded in Other Income.
- Restructuring: Recorded net restructuring charges of $1.3 million for the quarter and $3.1 million for the nine months, primarily related to severance costs in the Medical-Surgical Solutions segment.
Risks and Contingencies
- Legal Proceedings: Significant ongoing securities litigation regarding accounting improprieties at McKesson Information Solutions (formerly HBOC). Trial is scheduled for September 2005. The company states it is not feasible to estimate the potential loss.
- VA Contract Dispute: Competitor AmerisourceBergen filed a bid protest regarding McKesson's award of Prime Vendor status with the U.S. Department of Veterans Affairs. A hearing on delaying the contract start date is scheduled for February 2004.
- Acquisition Uncertainty: Entered a merger agreement to acquire Moore Medical Corp. for approximately $40 million. However, the target received a superior offer from a private investment firm, creating uncertainty regarding the completion of the deal.
- Customer Concentration: The loss of a large acute care customer in the Medical-Surgical segment necessitated a restructuring program to mitigate profit impact.
Investor Verification Checklist
- Working Capital Trends: Verify the sustainability of the increased investment in receivables and inventory ($1.05 billion increase in inventory and $751 million increase in receivables year-over-year) and its impact on future cash flow.
- Pharmaceutical Margins: Assess the long-term impact of the "evolving business model" in pharmaceutical distribution on gross margins, specifically the reduction in vendor incentives and the shift to warehouse sales.
- Legal Exposure: Monitor the status of the HBOC securities litigation and the VA bid protest, as outcomes could result in substantial payments or contract delays.
- Contract Losses: Review the progress of the international contracts in the Information Solutions segment that triggered the $71 million in total loss provisions to ensure no further accruals are needed.
- Debt Covenants: Confirm continued compliance with the debt-to-capital ratio covenant (currently 25.5% vs. 56.5% limit) given the increase in net debt.